Forms

Autosomal Recessive DOPA-Responsive Dystonia via the TH Gene

  • Summary and Pricing
  • Clinical Features and Genetics
  • Citations
  • Methods
  • Ordering/Specimens
Order Kits
TEST METHODS

Sequencing

Test Code Test Copy GenesIndividual Gene PriceCPT Code Copy CPT Codes
159 TH$840.00 81406 Add to Order
Targeted Testing

For ordering targeted known variants, please proceed to our Targeted Variants landing page.

Turnaround Time

The great majority of tests are completed within 18 days.

Clinical Sensitivity

This test will detect pathogenic variants in the TH gene in about 5% of patients with a clinical diagnosis of dystonia and marked and sustained response to levodopa treatment (Clot et al. 2009).

See More

See Less

Deletion/Duplication Testing via aCGH

Test Code Test Copy GenesIndividual Gene PriceCPT Code Copy CPT Codes
600 TH$690.00 81479 Add to Order
Pricing Comment

# of Genes Ordered

Total Price

1

$690

2

$730

3

$770

4-10

$840

11-30

$1,290

31-100

$1,670

Over 100

Call for quote

Turnaround Time

The great majority of tests are completed within 28 days.

Clinical Sensitivity

To date, only one large pathogenic deletion was reported in one patient (Ormazabal et al. 2011).

See More

See Less

Clinical Features

Autosomal recessive Dopa-responsive dystonia (AR-DRD) is a rare progressive neurometabolic disorder. It is heterogeneous in regard to the age of onset, clinical features, progression rate, and response to levodopa therapy. Clinical features include limb dystonia, hypokinesia, bradykinesia, truncal hypotonia, tremor, myoclonus, rigidity of extremities, walking difficulties, oculogyric crises, inexpressive faces, ptosis, autonomic disturbances, lethargy-irritability crises, sleep disturbances, and psychomotor developmental delay. AR-DRD is usually more severe and more complex than autosomal dominant DRD. Two forms of the disease can be distinguished.

1. TH-deficient dopa-responsive dystonia is characterized by onset in infancy, usually during the first year of life, and diurnal fluctuation. Symptoms are mild in the mornings and exacerbate during the day. Patients with TH-deficient dopa-responsive dystonia are successfully treated with low-doses of L-DOPA in combination with a decarboxylase inhibitor. Patients are usually able to conduct a normal life (Schiller et al. 2004).

2. Infantile Parkinsonism is characterized by an earlier onset, usually during the first six months of life, and more rapid progression. Additional distinguishing symptoms include complicated perinatal history, seizures and developmental motor delay. Response to L-DOPA therapy is less effective and was absent in about one third of treated patients (Willemsen et al. 2010; Sun et al. 2014).

In addition to these two phenotypes, various intermediary phenotypes with overlapping features have been described (Hoffmann et al. 2003; Furukawa et al. 2004).

Autosomal recessive DRD is less common than the dominant form of DRD. About 50 families have been reported worldwide (Verbeek et al. 2007; Clot et al. 2009; Willemsen et al. 2010).

Genetics

Autosomal recessive DRD is genetically heterozygous. Two genes have been implicated in the disease: TH and SPR (Lüdecke et al. 1995; Bonafe et al. 2001).

To date, about 60 different pathogenic variants in the TH gene have been reported. Most variants are missense. However, several truncating variants, including splice site variants and small frameshift deletions were also reported. Large pathogenic deletions appear to be rare. Only one such deletion has been reported (Ormazabal et al. 2011). Several variants in the promoter region have been documented to be pathogenic (Ribasés et al. 2007; Verbeek et al. 2007). Although heterozygous carriers are usually asymptomatic, exercise-induced stiffness has been reported in heterozygous family members (Furukawa et al. 2001).

Pathogenic variants in the TH gene have been reported in patients with AR-DRD from various geographic and ethnic origins (Verbeek et al. 2007; Willemsen et al. 2010; Al-Muslamani et al. 2014).

The TH gene encodes the tyrosine hydroxylase enzyme, a rate-limiting enzyme in the biosynthesis of catecholamines, including dopamine. It is expressed mainly in the brain and adrenal medulla.

Pathogenic variants in the TH gene have been documented to result in reduced levels of the tyrosine hydroxylase enzyme, which lead to low levels of cerebral L-DOPA (Lüdecke et al. 1995).

Testing Strategy

This test involves bidirectional DNA sequencing of all 14 coding exons and splice sites of the TH gene, and the region of the promoter that harbors the three known regulatory variants. The full coding sequence of each exon plus ~ 20 bp of flanking DNA on either side are sequenced. We will also sequence any single exon (Test #100) or pair of exons (Test #200) in family members of patients with known pathogenic variants or to confirm research results.

Indications for Test

Patients with infantile and childhood onset dystonia with a positive response to L-DOPA and no pathogenic variants in the GCH1 gene are candidates for this test.

Patients with atypical dystonia phenotypes and no pathogenic variants in the remaining genes associated with dystonia are also candidates (Sun et al. 2014).

Gene

Official Gene Symbol OMIM ID
TH 191290
Inheritance Abbreviation
Autosomal Dominant AD
Autosomal Recessive AR
X-Linked XL
Mitochondrial MT

Disease

Name Inheritance OMIM ID
Tyrosine Hydroxylase Deficiency AR 605407

Related Tests

Name
Autism Spectrum Disorders and Intellectual Disability (ASD-ID) Comprehensive Sequencing Panel with CNV Detection
Dystonia Sequencing Panel with CNV Detection

CONTACTS

Genetic Counselors
Geneticist
Citations
  • Al-Muslamani A.M. et al. 2014. Sultan Qaboos University Medical Journal. 14: e397-400. PubMed ID: 25097778
  • Bonafé L. et al. 2001. American Journal of Human Genetics. 69: 269-77. PubMed ID: 11443547
  • Clot F. et al. 2009. Brain. 132: 1753-63. PubMed ID: 19491146
  • Furukawa Y. et al. 2001. Neurology. 56: 260-3. PubMed ID: 11160968
  • Furukawa Y. et al. 2004. Annals of Neurology. 55: 147-8. PubMed ID: 14705130
  • Hoffmann G.F. et al. 2003. Annals of Neurology. 54 Suppl 6: S56-65. PubMed ID: 12891655
  • Lüdecke B. et al. 1995. Human Genetics. 95: 123-5. PubMed ID: 7814018
  • Ormazabal A. et al. 2011. Movement Disorders. 26: 1558-60. PubMed ID: 21465550
  • Ribasés M. et al. 2007. Molecular Genetics and Metabolism. 92: 274-7. PubMed ID: 17698383
  • Schiller A. et al. 2004. Neurology. 63: 1524-6. PubMed ID: 15505183
  • Sun Z.F. et al. 2014. Plos One. 9: e106388. PubMed ID: 25181484
  • Verbeek M.M. et al. 2007. Annals of Neurology. 62: 422-6. PubMed ID: 17696123
  • Willemsen M.A. et al. 2010. Brain. 133: 1810-22. PubMed ID: 20430833
Order Kits
TEST METHODS

Bi-Directional Sanger Sequencing

Test Procedure

Nomenclature for sequence variants was from the Human Genome Variation Society (http://www.hgvs.org).  As required, DNA is extracted from the patient specimen.  PCR is used to amplify the indicated exons plus additional flanking non-coding sequence.  After cleaning of the PCR products, cycle sequencing is carried out using the ABI Big Dye Terminator v.3.0 kit.  Products are resolved by electrophoresis on an ABI 3730xl capillary sequencer.  In most cases, sequencing is performed in both forward and reverse directions; in some cases, sequencing is performed twice in either the forward or reverse directions.  In nearly all cases, the full coding region of each exon as well as 20 bases of non-coding DNA flanking the exon are sequenced.

Analytical Validity

As of March 2016, we compared 17.37 Mb of Sanger DNA sequence generated at PreventionGenetics to NextGen sequence generated in other labs. We detected only 4 errors in our Sanger sequences, and these were all due to allele dropout during PCR. For Proficiency Testing, both external and internal, in the 12 years of our lab operation we have Sanger sequenced roughly 8,800 PCR amplicons. Only one error has been identified, and this was due to sequence analysis error.

Our Sanger sequencing is capable of detecting virtually all nucleotide substitutions within the PCR amplicons. Similarly, we detect essentially all heterozygous or homozygous deletions within the amplicons. Homozygous deletions which overlap one or more PCR primer annealing sites are detectable as PCR failure. Heterozygous deletions which overlap one or more PCR primer annealing sites are usually not detected (see Analytical Limitations). All heterozygous insertions within the amplicons up to about 100 nucleotides in length appear to be detectable. Larger heterozygous insertions may not be detected. All homozygous insertions within the amplicons up to about 300 nucleotides in length appear to be detectable. Larger homozygous insertions may masquerade as homozygous deletions (PCR failure).

Analytical Limitations

In exons where our sequencing did not reveal any variation between the two alleles, we cannot be certain that we were able to PCR amplify both of the patient’s alleles. Occasionally, a patient may carry an allele which does not amplify, due for example to a deletion or a large insertion. In these cases, the report contains no information about the second allele.

Similarly, our sequencing tests have almost no power to detect duplications, triplications, etc. of the gene sequences.

In most cases, only the indicated exons and roughly 20 bp of flanking non-coding sequence on each side are analyzed. Test reports contain little or no information about other portions of the gene, including many regulatory regions.

In nearly all cases, we are unable to determine the phase of sequence variants. In particular, when we find two likely causative mutations for recessive disorders, we cannot be certain that the mutations are on different alleles.

Our ability to detect minor sequence variants, due for example to somatic mosaicism is limited. Sequence variants that are present in less than 50% of the patient’s nucleated cells may not be detected.

Runs of mononucleotide repeats (eg (A)n or (T)n) with n >8 in the reference sequence are generally not analyzed because of strand slippage during PCR and cycle sequencing.

Unless otherwise indicated, the sequence data that we report are based on DNA isolated from a specific tissue (usually leukocytes). Test reports contain no information about gene sequences in other tissues.

Deletion/Duplication Testing Via Array Comparative Genomic Hybridization

Test Procedure

Equal amounts of genomic DNA from the patient and a gender matched reference sample are amplified and labeled with Cy3 and Cy5 dyes, respectively. To prevent any sample cross contamination, a unique sample tracking control is added into each patient sample. Each labeled patient product is then purified, quantified, and combined with the same amount of reference product. The combined sample is loaded onto the designed array and hybridized for at least 22-42 hours at 65°C. Arrays are then washed and scanned immediately with 2.5 µM resolution. Only data for the gene(s) of interest for each patient are extracted and analyzed.

Analytical Validity

PreventionGenetics' high density gene-centric custom designed aCGH enables the detection of relatively small deletions and duplications within a single exon of a given gene or deletions and duplications encompassing the entire gene. PreventionGenetics has established and verified this test's accuracy and precision.

Analytical Limitations

Our dense probe coverage may allow detection of deletions/duplications down to 100 bp; however due to limitations and probe spacing this cannot be guaranteed across all exons of all genes. Therefore, some copy number changes smaller than 100-300 bp within a targeted large exon may not be detected by our array.

This array may not detect deletions and duplications present at low levels of mosaicism or those present in genes that have pseudogene copies or repeats elsewhere in the genome.

aCGH will not detect balanced translocations, inversions, or point mutations that may be responsible for the clinical phenotype.

Breakpoints, if occurring outside the targeted gene, may be hard to define.

The sensitivity of this assay may be reduced when DNA is extracted by an outside laboratory.

Order Kits

Ordering Options


myPrevent - Online Ordering
  • The test can be added to your online orders in the Summary and Pricing section.
  • Once the test has been added log in to myPrevent to fill out an online requisition form.
REQUISITION FORM
  • A completed requisition form must accompany all specimens.
  • Billing information along with specimen and shipping instructions are within the requisition form.
  • All testing must be ordered by a qualified healthcare provider.

SPECIMEN TYPES
WHOLE BLOOD

(Delivery accepted Monday - Saturday)

  • Collect 3 ml -5 ml (5 ml preferred) of whole blood in EDTA (purple top tube) or ACD (yellow top tube). For Test #500-DNA Banking only, collect 10 ml -20 ml of whole blood.
  • For small babies, we require a minimum of 1 ml of blood.
  • Only one blood tube is required for multiple tests.
  • Ship blood tubes at room temperature in an insulated container. Do not freeze blood.
  • During hot weather, include a frozen ice pack in the shipping container. Place a paper towel or other thin material between the ice pack and the blood tube.
  • In cold weather, include an unfrozen ice pack in the shipping container as insulation.
  • At room temperature, blood specimen is stable for up to 48 hours.
  • If refrigerated, blood specimen is stable for up to one week.
  • Label the tube with the patient name, date of birth and/or ID number.

DNA

(Delivery accepted Monday - Saturday)

  • Send in screw cap tube at least 5 µg -10 µg of purified DNA at a concentration of at least 20 µg/ml for NGS and Sanger tests and at least 5 µg of purified DNA at a concentration of at least 100 µg/ml for gene-centric aCGH, MLPA, and CMA tests, minimum 2 µg for limited specimens.
  • For requests requiring more than one test, send an additional 5 µg DNA per test ordered when possible.
  • DNA may be shipped at room temperature.
  • Label the tube with the composition of the solute, DNA concentration as well as the patient’s name, date of birth, and/or ID number.
  • We only accept genomic DNA for testing. We do NOT accept products of whole genome amplification reactions or other amplification reactions.

CELL CULTURE

(Delivery preferred Monday - Thursday)

  • PreventionGenetics should be notified in advance of arrival of a cell culture.
  • Culture and send at least two T25 flasks of confluent cells.
  • Some panels may require additional flasks (dependent on size of genes, amount of Sanger sequencing required, etc.). Multiple test requests may also require additional flasks. Please contact us for details.
  • Send specimens in insulated, shatterproof container overnight.
  • Cell cultures may be shipped at room temperature or refrigerated.
  • Label the flasks with the patient name, date of birth, and/or ID number.
  • We strongly recommend maintaining a local back-up culture. We do not culture cells.
loading Loading... ×